Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer.
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000005488
- Lead Sponsor
- Multicenter Clinical Study Group Osaka Colorectal Cancer Treatment Group
- Brief Summary
Response rate
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are inadequate by investigator's decision.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival, Overall survival, Safety profile, Conversion rate of nonresectable liver metastases to resectable